(PA45) Studies on Bio-Normalizer’s Anti Cancer Properties

Title Studies on Bio-Normalizer’s Anti Cancer Properties
Author J.A.Osato; M. Simonoff; G.Bernas; L.Korkina
Publisher 19th Annual Scientific Meeting : Science for Better Health
Organ
Category

 

NATIONAL ACADEMY OF SCIENCE

AND TECHNOLOGY

19TH ANNUAL SCIENTIFIC MEETING

Theme: “Science for Better Health”

Lunching of the S&T Centennial Celebration

The Westin Philippine Plaza

CCP Complex, Roxas Boulevard

Pasay City

9-10 July 1997

 

 


17. STUDIES ON BIO-NORMALIZER’S

ANTI-CANCER PROPERTIES

 

JAMES AKIRA OSATO1, MONIQUE SIMONOFF2, GLORIA C. BERNAS3, and LUDMILA G. KORKINA4

 

1Osato Research Institute,
#12 Minami-machi Bairin Gifu 500 Japan

2Laureat de L ‘Academie de Medecine
Centre D’Etudes Nucleaires De Bordeaux Gradignan
BP 120 F33175 Gradignan Cedex, France

 

3Research Center for the Natural Sciences
University of Santo Tomas
1008 Espana, Manila

 

4Russian Institute of Pediatric Hematology,

Moscow, Russia

Bio-Normalizer (BN), a semi-natural fermented health food has free radical regulatory and immunomodulatory functions. A comprehensive battery of experiments was done to determine its applicability in cancer therapy. Its effects on human monocyte and rat peritoneal macrophage was initially measured in vitro. BN was found to enhance the formation of tumor necrosis factor (TN F)-α by the phagocytes aside from stimulating intra-and extracellular superoxide production. BN’s cytotoxic activity against human cancer cell lines like laryngeal carcinoma (Hep-2), bronchioalveolar adenocarcinoma (SLNI-52), lung adenocarcinoma (A549) and cervical epitheloid carcinoma (HeLa) was evaluated using tetrazolium-based colorimetric assay. BN demonstrated cell killing effect on all the cells tested with Hep-2 being the most sensitive. The effect of BN on cisplatin’s and melphalan’s antiproliferative activity on human ovarian carcinoma cell was also investigated in vitro. BN was proven to inhibit cisplatin’s but not melphalan’s cytostatic activity. Finally, a clinical trial on patients with acute lympho- and myeloleukemias undergoing therapeutic irradiation was conducted. Results showed that BN administration protected them from the neurologic symptoms of irradiation. It increased the superoxide dismutase (SOD) activity and blood cell level of reduced glutathione (GSH). Based on these findings, BN could be recommended as a supportive care in cancer therapy.

 

Keywords: bio-normalizer, anti-cancer, cancer therapy